Introduction
Actos is manufactured by Takeda Pharmaceuticals of Japan and is marketed in the U.S. by Eli Lilly & Co. Since pioglitazone, the single active ingredient in Actos, was first approved by the FDA in 1999, doctors have prescribed Actos to millions of diabetes patients.
History of the Case
In its June 2011 warning, the FDA said patients who had used pioglitazone for longer than 12 months showed a 40 percent increase in the risk of developing bladder cancer.
Injuries Related to Product
SIGNS OF BLADDER CANCER INCLUDE:
- Bloody or reddish urine
- Frequent urination
- An urgent need to urinate
- Urine leakage (incontinence)
- Pain during urination
- Pain in the back or lower abdomen
